Antidote

SEPTEMBER 12, 2022

There are many factors one should consider before deciding to enroll in a clinical trial. Though every clinical trial is designed to help researchers advance their knowledge about a specific condition, the details regarding a study’s duration, risks, benefits, and required time commitment can vary. When determining how to participate in clinical trials, these elements are all good things to discuss with the research team to determine if a study is a good fit.

Clinical Trials 97

Clinical Trials Trials Research 97

Drug Discovery Today

SEPTEMBER 16, 2022

Why opening up communication channels can stop the spread of misinformation

Laboratories 113

Laboratories 113

Drug Patent Watch

SEPTEMBER 15, 2022

This chart shows the pharmaceutical companies with the most patents in Ireland. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Ireland? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceutical Companies 92

Pharmaceutical Companies Pharmaceuticals Drugs 92

Drug Channels

SEPTEMBER 16, 2022

Today’s guest post comes from Edward Hensley, Chief Commercial Officer at AssistRx. Edward compares the pros and cons of electronic benefit verification using artificial intelligence, direct connectivity, or data connectivity. He also describes the circumstances where each solution provides the greatest value. To learn more, download AssistRx’s free eBook: Specialty Drug Patient Support Programs: 2022 Progress Report.

Drugs 85

Drugs 85

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Treatment

Olympian Clinical Research

SEPTEMBER 16, 2022

Nearly 6.2 million Americans were living with Alzheimer’s disease in 2021, according to the Centers for Disease Control and Prevention (CDC). Alzheimer’s disease is the seventh leading cause of death in the United States and is a devastating disease that can rob people of their memories and lives. But what if there were steps you could take to potentially prevent Alzheimer’s from happening in the first place?

Disease 52

Disease Clinical Trials Clinical Research Trials 52

Antidote

SEPTEMBER 15, 2022

Successful clinical trial patient recruitment is a multi-step process that is worth taking the time to thoroughly understand. Clinical trial recruitment companies often make mention of thorough research, rigorous testing, and continuous optimization — but what does that mean in practical terms?

Clinical Trials 52

Clinical Trials Trials Research 52

Drug Channels

SEPTEMBER 13, 2022

By now, you have already read innumerable articles explaining what’s in the new Inflation Reduction Act of 2022 (IRA; P.L. 117-169). Today, I want to highlight three significant—and presumably unintended—drug channel consequences from the hastily-passed IRA legislation. These include disruption to the now-booming biosimilar market, the prospects of physician/hospital vertical integration that will raise commercial healthcare costs and expand 340B, and the need for complex new processes to admini

Biosimilars 74

Biosimilars Pharmacy Hospitals Marketing 74

Crown Bioscience

SEPTEMBER 15, 2022

Using whole genome sequencing to better understand PDX genomic profiles is a highly comprehensive method for analyzing whole genomes. By incorporating WGS into preclinical tumor studies, the genomic and pathogenic features of cancers can be better understood, and translational biomarkers can be identified more efficiently.

52

52

NIH Director's Blog: Drug Discovery

SEPTEMBER 13, 2022

Each year, more than 2.8 million people in the United States develop bacterial infections that don’t respond to treatment and sometimes turn life-threatening [1]. Their infections are antibiotic-resistant, meaning the bacteria have changed in ways that allow them to withstand our current widely used arsenal of antibiotics. It’s a serious and growing health-care problem here and around the world.

Doctors 52

Doctors Science Disease Drugs 52

Drug Patent Watch

SEPTEMBER 15, 2022

Annual Drug Patent Expirations for EPRONTIA Eprontia is a drug marketed by Azurity and is included in one NDA. It is available from one supplier. The generic ingredient in EPRONTIA…. The post New patent for Azurity drug EPRONTIA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Clinical Trials

Drug Channels

SEPTEMBER 14, 2022

I invite you to join me for three new video webinars during 2023. These live, interactive events will be broadcast via Zoom from the Drug Channels Video studio in beautiful downtown Philadelphia. During these events, I'll address the latest issues confronting the U.S. drug channel. Topics will be determined based on what’s happening—trends, policy changes, company announcements, and more.

Drugs 72

Drugs Marketing 72

LifeSciVC

SEPTEMBER 15, 2022

By Joshua Brumm, CEO of Dyne Therapeutics, as part of the From The Trenches feature of LifeSciVC By all accounts, 2022 did not start according to plan for the biotech industry. The U.S. economy and growth stocks struggled with the broader biotech index down by more than 45 percent through the first half of the year. Throughout my career in biotech, I have learned that this industry is filled with twists and turns and, at times, setbacks.

Trials 52

Trials Clinical Trials Clinical Development Therapies 52

Pharma Manufacturing

SEPTEMBER 12, 2022

Research into nanomaterials has opened the door to new therapeutic strategies

Research 40

Research 40

Drug Patent Watch

SEPTEMBER 14, 2022

This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Finland. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…. The post Which pharmaceutical companies have the most SPCs in Finland? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals 52

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Clinical Trials

Drug & Device Law

SEPTEMBER 14, 2022

From the defense perspective, the worst thing about a mass tort is that it is so … massive. The more the merrier? No way. The presence of multiple plaintiffs signals to the jury that something must be wrong with the product. Don’t believe us? We think there is research to support our dislike of consolidation but, even beyond that, our eyes and ears don’t lie.

Doctors 52

Doctors Production Research Drugs 52

Drug Patent Watch

SEPTEMBER 14, 2022

Annual Drug Patent Expirations for VENCLEXTA Venclexta is a drug marketed by Abbvie Inc and is included in one NDA. It is available from one supplier. There are eight patents…. The post New patent for Abbvie Inc drug VENCLEXTA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

SEPTEMBER 13, 2022

This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Italy. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…. The post Which pharmaceutical companies have the most SPCs in Italy? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals 52

Drug Patent Watch

SEPTEMBER 13, 2022

Annual Drug Patent Expirations for CIPRODEX Ciprodex is a drug marketed by Novartis and is included in one NDA. It is available from three suppliers. There are four patents protecting…. The post New patent expiration for Novartis drug CIPRODEX appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Advertisement

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

Clinical Trials

Drug Patent Watch

SEPTEMBER 13, 2022

Annual Drug Patent Expirations for MAVENCLAD Mavenclad is a drug marketed by Emd Serono Inc and is included in one NDA. It is available from one supplier. There are four…. The post New patent for Emd Serono drug MAVENCLAD appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

SEPTEMBER 13, 2022

Annual Drug Patent Expirations for YUTIQ Yutiq is a drug marketed by Eyepoint Pharms and is included in one NDA. There is one patent protecting this drug. This drug has…. The post New patent for Eyepoint Pharms drug YUTIQ appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

SEPTEMBER 12, 2022

This chart shows the drugs with the most patents in Lithuania. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Lithuania? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceuticals 52

Pharmaceuticals Drugs 52

Drug Patent Watch

SEPTEMBER 11, 2022

This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Sweden. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…. The post Which pharmaceutical companies have the most SPCs in Sweden? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals 52

Drug Patent Watch

SEPTEMBER 11, 2022

Annual Drug Patent Expirations for VANOS Vanos is a drug marketed by Bausch and is included in one NDA. It is available from one supplier. There are three patents protecting…. The post New patent expiration for Bausch drug VANOS appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

SEPTEMBER 11, 2022

Annual Drug Patent Expirations for BREO+ELLIPTA Breo Ellipta is a drug marketed by Glaxo Grp Ltd and is included in one NDA. It is available from two suppliers. There are…. The post New patent expiration for Glaxo Grp drug BREO ELLIPTA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

SEPTEMBER 11, 2022

Annual Drug Patent Expirations for ANORO+ELLIPTA Anoro Ellipta is a drug marketed by Glaxosmithkline and is included in one NDA. It is available from one supplier. There are fifteen patents…. The post New patent expiration for Glaxosmithkline drug ANORO ELLIPTA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

SEPTEMBER 11, 2022

Annual Drug Patent Expirations for TRELEGY+ELLIPTA Trelegy Ellipta is a drug marketed by Glaxosmithkline and is included in one NDA. It is available from one supplier. There are fifteen patents…. The post New patent expiration for Glaxosmithkline drug TRELEGY ELLIPTA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

SEPTEMBER 11, 2022

Annual Drug Patent Expirations for ORAVIG Oravig is a drug marketed by Galt Pharms and is included in one NDA. It is available from one supplier. There are three patents…. The post New patent expiration for Galt Pharms drug ORAVIG appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

SEPTEMBER 10, 2022

This chart shows the drugs with the most patents in Bulgaria. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Bulgaria? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceuticals 52

Pharmaceuticals Drugs 52

Drug Patent Watch

SEPTEMBER 13, 2022

BREO ELLIPTA (fluticasone furoate; vilanterol trifenatate) Glaxo grp ltd Patent: 7,776,895 Expiration: Sep 11, 2022 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business…. The post Drug Patent Expirations for the Week of September 11, 2022 appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 40

Drugs Pharmaceuticals 40

Pharma Manufacturing

SEPTEMBER 14, 2022

Hint: It’s not by raising prices

40

40

Drug & Device Law

SEPTEMBER 15, 2022

A little over a year ago, we discussed one of the best decisions we had ever read on why comparative risk claims – premised on a manufacturer’s alleged failure to warn that a competing product was supposedly “safer” – are both statistically invalid and practically impossible. That decision, Nelson v. C.R. Bard, Inc. , 553 F. Supp.3d 343 (S.D. Miss. 2021), explained at length both how product “comparisons,” if based on the FDA’s voluntary “MAUDE” adverse event reporting system are inherently sus

Production 52

Production Packaging International Research 52

Drug & Device Law

SEPTEMBER 12, 2022

We recently received a copy of Pfaff v. Merck & Co. , No. 12-md-02331 (BMC), slip op. (E.D.N.Y. Sept. 9, 2022), and the decision has a number of useful – for our side – rulings concerning branded drug preemption post- Merck Sharp & Dohme Corp. v. Albrecht , 139 S. Ct. 1668 (U.S. 2019). Pfaff is a straggler from the In re Propecia (Finasteride) Products Liability Litigation MDL, most of which settled in 2019.

FDA 59

FDA FDA Approval Regulations International 59